4.4 Article

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

期刊

TRIALS
卷 23, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13063-022-06370-1

关键词

Staphylococcus aureus; Bacteremia; Right-sided endocarditis; Dalbavancin; Randomized controlled trial

资金

  1. National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) [UM1AI104681]
  2. Division of Microbiology and Infectious Diseases (DMID)/NIAID/NIH
  3. Durham Center of Innovation to Accelerate Discovery and Practice Transformation Grant [CIN 13-410]

向作者/读者索取更多资源

The DOTS trial aims to compare the efficacy of dalbavancin with standard parenteral antibiotic therapy in treating complicated Staphylococcus aureus bacteremia by evaluating the Desirability of Outcome Ranking (DOOR) at day 70 after treatment.
Background: Staphylococcus aureus bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15-50%. Treatment typically requires prolonged administration of parenteral therapy, itself associated with high costs and potential catheter-associated complications. Dalbavancin is a lipoglycopeptide with potent activity against Staphylococcus and a long half-life, making it an appealing potential therapy for S. aureus bacteremia without the need for durable central venous access. Methods: DOTS is a phase 2b, multicenter, randomized, assessor-blinded, superiority, active-controlled, parallel-group trial. The trial will enroll 200 adults diagnosed with complicated S. aureus bacteremia, including definite or possible right-sided infective endocarditis, who have been treated with effective antibiotic therapy for at least 72 h (maximum 10 days) and with subsequent clearance of bacteremia prior to randomization to study treatment. Subjects will be randomized 1:1 to complete their antibiotic treatment course with either two doses of dalbavancin on days 1 and 8, or with a total of 4-8 weeks of standard intravenous antibiotic therapy. The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at day 70 for patients randomized to dalbavancin versus standard of care. Key secondary endpoints include quality of life outcomes and pharmacokinetic analyses of dalbavancin. Discussion: The DOTS trial will establish whether dalbavancin is superior to standard parenteral antibiotic therapy for the completion of treatment of complicated S. aureus bacteremia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据